Evidence map›Paper›PMID 38615521›Full record

ArticlePsychiatry research2024

Mechanisms of therapeutic change after psychedelic treatment in OCD.

Gayle Maloney, Terence Ching, Stephen A Kichuk, Christopher Pittenger, Benjamin Kelmendi

Open access · greenAbstract read
In one paragraph

Article in Psychiatry research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Gayle MaloneyDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States; Perth OCD Clinic, Perth, Australia. Electronic address: gayle.maloney@perthocdclinic.com.au.
Terence ChingDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Stephen A KichukDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Christopher PittengerDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States; Yale Child Study Center, Yale University School of Medicine, New Haven, CT, United States; Department of Psychology, Yale University, New Haven, CT, United States; Wu Tsai Institute, Yale University, New Haven, CT, United States; Center for Brain and Mind Health, Yale University School of Medicine, New Haven, CT, United States.
Benjamin KelmendiDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
Yale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Patient Oriented Research and Mentorship and Training in Functional Neuroimaging of Obsessive-Compulsive DisorderK24MH121571 · NIMH · YALE UNIVERSITY · PI PITTENGER, CHRISTOPHER JOHN · 2020 to 2024
$900k
The neural correlates of the effects of psilocybin in OCD: randomized controlled studyK23MH122777 · NIMH · YALE UNIVERSITY · PI KELMENDI, BENJAMIN · 2021 to 2024
$758k
NCATS NIH HHS UL1 TR001863NIMH NIH HHS K23 MH122777NIMH NIH HHS K24 MH121571
6 · The paper itself

Abstract

Novel treatments are required for the 30-50% of individuals with obsessive-compulsive disorder (OCD) who remain resistant to first-line pharmacological and psychotherapeutic treatments. Recent pilot data suggest benefit from psilocybin-assisted psychotherapy (PAP) and from imagery rescripting (ImRs). We explore psychological mechanisms of change underpinning both interventions that appear to allow for reprocessing of negative emotions and core beliefs associated with past aversive events. A next critical step in PAP is the development of psychotherapeutic frameworks grounded in theory. We propose that basing PAP on an ImRs framework may provide synergistic benefits in symptom reduction, modification of core beliefs, and value-based living.

Indexed as

HallucinogensObsessive-Compulsive DisorderPsilocybinHumansImagery, PsychotherapyHallucinogensPsilocybinImagery rescripting (ImRs)Obsessive-compulsive disorder (OCD)Psilocybin-assisted psychotherapy (PAP)Psychological mechanisms

Identifiers

PMID38615521
PMCPMC11190873
OpenAlexW4394061312

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.